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Introduction
The conference "Application of Molecular Biomarkers in
Epidemiology," was held at the National Institute of En-
vironmental Health Sciences, February 21-22, 1990. The
primary objective ofthe conference was to provide an up-to-date
review ofsome ofthe molecular biomarkers currently available
in order to promote discussion between laboratory scientists and
epidemiologists on the utility ofthese biomarkers. Biomarkers
are indicators of molecular and cellular events in biological
systems that may allow epidemiologists and other health profes-
sionals to better examine the relationships between environmen-
tal hazards and human health effects. Biomarkers fall into three
basic categories: biomarkers ofdose, effect, and susceptibility.
Many laboratories are using molecular biology and sophisticated
chemical techniques to develop such biomarkers, but their ap-
plication in epidemiological studies has been quite limited so far.
The current and future use of biomarkers in epidemiological
studies at Superfund sites and in the workplace was discussed.
This conference report is formatted somewhat differently from
the other reports ofthe Superfund Basic Research Program in its
series of conferences in 1990. The biomarkers conference was
different in its presentation in that the series of short talks by the
participants were used as discussion points to be expanded at the
various round tables. The conference consisted of six sessions of
15-min presentations and two round-table discussions. On the
first day, there were two sessions on biomarkers of car-
cinogenesis and biomarkers ofchemical exposure, which were
followed by a round-table discussion on the usefulness of these
biomarker methods in epidemiology. A further session of talks
on correlation studies in animal models followed. On the second
day, there were three sessions of 15-min talks followed by a 2 hr
round-table discussion at the end ofthe day. The first two sessions
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described biomarkers of individual phenotypic variability and
biomarkers ofhealth effects other than cancer, and the last ses-
sion focused on the current use ofbiomarkers in epidemiological
studies. A summary of the conference program is provided in
the Appendix.
Biomarkers of Carcinogenesis
The first session was chaired by M. T. Smith (University of
California, Berkeley) and . B. Weinstein (Columbia University).
Smith began the session by recounting recent progress in our
understanding of the cancer process and the implied lessons for
biomarkers. Work by Vogelstein and others clearly indicates that
genetic alterations occur throughout the cancer process.
Moreover, these genetic changes are not only point mutations,
but chromosome-wide events such as aneuploidy-induction and
translocations. Screening chemicals for their ability to induce
genetic damage should therefore involve looking at many dif-
ferent end points.
Molecular biology advances should allow investigators to
evaluate chemicals much more rapidly than current cytogenetic
approaches. W. Thilly (Massachusetts Institute ofTechnology)
characterized an approach that involves the use of a high-fidelity
polymerase chain reaction and denaturing gradient gel elec-
trophoresis. This method allows his group to amplify specific
segments of DNA (e.g. an exon or coding region of the gene
coding for hypoxanthine-guanine phosphoribosyl transferase;
hprt) and to study the spectrum ofmutations produced by chem-
ical exposure and by spontaneous/background events. Thilly
described mutational spectra produced by various chemicals in-
cluding hydrogen peroxide and spontaneous events, and showed
how they differ markedly. He suggested that this rapid and sim-
ple methodology could be used on large numbers ofpeople, in-
dividually and as pooled samples, to identify mutational spectra
characteristic of particular chemical exposures. Thilly's ap-
proach of looking directly at the genotype differs from, but is
complementary to, that taken by R. Albertini (University ofVer-
mont), who addressed the selection of lymphocytes with a mu-
tant phenotype resulting from changes in their hprt gene. These
lymphocytes can then be analyzed for the nature ofthe mutations
in hprt. Albertini recounted how deletions at least as large as 5
megabases can be tolerated at hprt locus (on the X-chromosome)
and how different clones of lymphocytes can be produced by
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different types ofmutation at hprt. Albertini's group has shown
that the mutant frequency at hprt in newborns is much lower than
in adults and increases with age. Moreover, hprt in lymphocytes is
sensitive to smoking. Thus, epidemiological studies using hprt
mutational analysis would have to control for both age and
smoking.
Another gene that is used to analyze for genetic mutation in
humans is the gene that codes for the glycophorin A protein on
the surface of red blood cells. W. Bigbee (Lawrence Livermore
National Laboratory) reported on the development of state-of-
the-art flow cytometric methods to measure mutations in the
glycophorin A gene. Because red blood cells do not contain
DNA, the red mutational events must occur in the bone marrow
precursor cells. Thus, glycophorin A is particularly suitable for
screening human exposure to mutagenic chemicals that act on the
bone marrow to potentially cause leukemia and other hemato-
logical disorders. This group recently published a new version
ofthe glycophorin A assay that can be performed on commercial-
ly available flow cytometers.
Different methods of measuring micronuclei (small DNA-
containing membrane-bound vesicles outside the main cell
nucleus) that arise via chromosome lag or fragmentation in per-
ipheral blood cells were reported on by J. T. MacGregor (SRI
International). Micronuclei are potentially important for the
detection of aneuploidogens and clastogens.
G. Lucier (National Institute of Environmental Health
Sciences) reported how his group has compared different
biomarkers in vitro including correlating DNA adduct formation
with various genetic end points. One new assay of genetic
damage they have helped develop measures nucleoid sedimen-
tation and correlates closely with DNA strand breakage.
At the end of the session, Weinstein discussed the need for
markers ofepigenetic events in carcinogenesis as well as ones of
genetic alterations. He reviewed the need for biomarkers of
clonal cell proliferation and discussed the role of increased
protein kinase C activity in promoting cancer. His group is
studying the relationship between increased "phorbin" gene
expression and protein kinase C activation. They plan to measure
release ofthe phorbin gene product into the serum as a possible
marker of this activation and clonal cell proliferation.
Biomarkers of Chemical Exposure
The second session began with B. Hammock (University of
California, Davis) reviewing and evaluating immunological ap-
proaches to assess human exposure to toxic chemicals. He related
how immunoassays could be used in practical as well as mecha-
nistic studies, in environmental monitoring to study food
residues, groundwater contamination, and spills at waste
disposal sites. Biological monitoring could also be facilitated, as
immunoassays for a number of protein and DNA adducts have
been developed. Another potential use of antibodies is the
cleanup of samples by immunoaffinity chromatography before
more elaborate chemical analysis.
R. Haas (California Department ofHealth Services) expanded
upon this dialogue, reporting on the production ofantibodies to
detect altered blood proteins for biological monitoring. He
depicted attempts to synthesize hemoglobin adducts of styrene
oxide and hydroquinone, and to generate antibodies to these
modified blood proteins. The major obstacle to this procedure
has been the need to overcome the extreme immunogenicity of
hemoglobin, so that a minor modification by a particular en-
vironmental toxicant may not lead to production of antibodies
against the adduct, only against hemoglobin. Both Hammock
and Haas stressed the importance ofhapten synthesis. Covering
the functional group ofimportance during coupling to a carrier
is a common cause of failure to produce the desired antibodies.
The formation of polycyclic hydrocarbon esters in human
hemoglobin and their characterization by synchronous fluor-
escence spectrometry was reported on by P. Skipper (Massa-
chusetts Institute of Technology). Using this state-of-the-art
technique, his group found in human blood average levels of3-10
pole of benzo[a]pyrene/g globin, which was unaffected by
smoking status. A new method for looking at cysteine residues
or cysteinyl adducts ofblood proteins was recounted by S. Rap-
paport (University ofNorth Carolina, Chapel Hill). Raney nickel
is used to cleave the C-S bond between the adducted chemical
and the cysteine residue and to subsequently measure the re-
leased product. His group has thus measured adducts formed
between styrene oxide and hemoglobin or albumin in the blood
of styrene-exposed workers. Using data from both in vitro and
in vivo experiments, Raney determined the amount ofalkylation
by styrene oxide. He calculated that the method he described
could detect exposures between 0.4 and 4.0 ppm in workers and
approximately 0.2-2.0 ppm in the general population, The
method, which should be applicable to many other chemicals,
is being refined to improve sensitivity.
DNA-protein crosslinks are a major form of genetic damage
that can be readily analyzed. M. Costa (New York University)
illustrated that in cells exposed to cisplatinum or chromium VI,
four major proteins were complexed to the DNA. Costa's group
has unambiguously identified the protein crosslinked to theDNA
as actin, based on proteolytic maps, reaction with an actin an-
tibody, and alterations in restriction enzyme digestion ofDNA
containing the crosslinked protein. However, when cells are ex-
posed to formaldehyde, histones, not actin, are complexed to the
DNA. Thus, particular classes of chemicals may produce dif-
ferent protein-DNA crosslinks. In addition to being a promising
biomarker of exposure, DNA-protein crosslinking is a major
form of genetic damage and one that persists during cell pro-
liferation. Costa suggested this approach could be used to iden-
tify exposure to particular groups of toxic chemicals and also
delineated a new technology for measuring DNA-protein
crosslinks that relies on SDS-PAGE gel electrophoresis and
electroblotting.
Recounting his experience in measuring DNA adducts in
human populations, K. Hemminki (University of Helsinki)
described using the 32P-postlabeling procedure and im-
munoassays to determine the formation ofDNA adducts in Fin-
nish foundry workers. Rather than absolute quantitation of
polycyclic aromatic hydrocarbon (PAH) DNA adduct formation,
he used a score of adduct formation to express his results. He
gave the foundry workers a 2.1 adduct score. After vacation, they
had a 1.0 adduct score, demonstrating that adduct levels were
transient and stable for only approximately 1 month. Hemminki
then compared PAH-DNA adducts in Polish foundry workers
and in local and rural residents. The score in local residents was
almost as high as in the foundry workers, both of which were
significantly higher than in the rural area. This emphasizes the
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importance ofassessing background environmental exposure in
any studies ofworker populations. He further stated that quan-
titative aspects of 32P-postlabeling were not sufficiently studied
and described the difficulties in producing quantitative numbers
with these methods. 32P-postlabeling can best be used to assess
relative exposures rather than absolute levels of exposure/dose.
Urinary metabolites can also be used to assess chemical ex-
posures. While these may be transient in nature, it is important
to note that a large majority of chemicals are converted mainly
to urinary metabolites, which makes this relatively simple
screening approach widely applicable.
A. Buckpitt (University of California, Davis) defined the po-
tential for monitoring naphthalene exposure through urinary
metabolites. Because the IS,2R epoxide ofnaphthalene is the ma-
jor binding species and pulmonary toxicant, Buckpitt related the
importance of screening for the IS, 2R mercapturic acid in urine
when quantitating the biologically important dose of naphtha-
lene. By comparing it to the 1R,2S levels, one can determine the
ability of people to convert naphthalene to an active metabolite
capable of causing injury to the lung.
Round-Table Discussion 1
The charge to the first round-table discussants was to evaluate
whether the biomarkers described in the first two sessions
(biomarkers of carcinogenesis and biomarkers of chemical
exposure) meet the necessary epidemiological criteria. The
round-table discussion clearly indicated the tremendous com-
munication gap between many practicing epidemiologists and
those laboratory scientists currently developing molecular
biomarkers. The major points raised can be summarized as
follows. Epidemiologists need well-characterized, simple, sen-
sitive, and inexpensive ways ofassessing exposure and health ef-
fects or predictors of health effects that can be applied to large
populations. Laboratory scientists tend to want to be on the cut-
ting edge of the development of new biomarkers and are con-
tinuously pushing forward using the latest techniques (and
associated jargon) in developing such methods. Although
laboratory scientists tend to be consistently dissatisfied with their
present product, epidemiologists are willing to use these
methods before all the problems associated with the methods are
worked out.
Epidemiologists argue that the utility of the new technology
has to be tested in the field, where populations are exposed to a
variety ofpotentially hazardous substances. In their study ofthe
associations between exposure to toxic chemicals and various
disease end points, epidemiologists often find exposure assess-
ment to be one ofthe main problems ofepidemiological studies.
Epidemiologists are eager to try out new tools that may prove
to be more sensitive and accurate in order to better understand
the relationships between the processes leading from exposure
to disease. This applies especially to environmental exposures
that affect many people, yet the responses elicited by exposure
are relatively low and homogeneously distributed so that new and
more sensitive detection methods are sorely needed. Epidemi-
ologists also pointed out that laboratory scientists need to be
aware that the methods they develop can only be applied in
accessible tissues and that this tissue may have to be frozen or
preserved in some manner before analysis. Issues relating to
stability ofbiomarkers during storage were therefore discussed,
and laboratory scientists were encouraged to study this in more
detail. R. Montesano (International Agency for Research on
Cancer) raised the point that the prevalence of genetically
susceptible subpopulations may significantly influence the range
of background levels in the general population, and better
characterization of these subgroups will be essential.
Correlation Studies in Animal Models
J. Swenberg (University of North Carolina, Chapel Hill) il-
lustrated how his group has measured DNA adduct formation in
tissues of rodents exposed to the carcinogens vinyl chloride and
ethylene oxide. Ethylene oxide is a brain carcinogen in rodents
and forms the most DNA adducts in this tissue, but it also pro-
duces considerable levels ofDNA adducts in nontarget tissues.
Studies in animal models can therefore be used to correlate a par-
ticular biomarker with subsequent carcinogenic outcome.
Comparing various biomarkers in rodent studies using
benzene, butadiene, and other compounds, R. Henderson
(Lovelace Inhalation Toxicology Research Institute), reported on
how 82-91% ofthe metabolized dose ofthese chemicals was con-
verted to urinary metabolites detectable for only 48 hr. She
pointed out, however, that given this large percentage conversion
rate, urinary metabolites should be an effective biomarker ofcon-
tinuous low-level exposures. Only 0.1-0.4% ofthe metabolized
dose was converted to hemoglobin adducts, but such adducts do,
ofcourse, accumulate. She further warned ofthe dangers of us-
ing rat hemoglobin as a surrogate for human hemoglobin, as the
former is more sensitive to alkylation. Mouse hemoglobin seems
to be a far more appropriate animal model.
At the end ofthe first day, G. Wogan (Massachusetts Institute
ofTechnology) reported on work in his laboratory that correlated
the formation ofDNA adducts in rat liver with the activation of
ras oncogenes and the subsequent development ofliver tumors.
The analytical methods used to detect their presence at an early
stage are readily applicable to human tissues and may therefore
provide a means for detection ofearly premalignant changes in
humans exposed to environmental carcinogens. Wogan has
shown that chemicals representative of the generic class of
genotoxic chemicals (i.e., chemicals that have the ability to
damage DNA and cause mutations and cancer) have been shown
to activate oncogenes by inducing similar mutations, and detec-
tion ofthese in preneoplastic cells may provide a sensitive means
to detect hazardous environmental exposures.
Biomarkers of Individual
Phenotypic Variability
The second day began with descriptions of several new ways
of assessing differences in the ability of humans to metabolize
various chemicals, either to toxic or nontoxic products. There
are substantial differences in the levels of particular enzymes
involved in the metabolism of chemicals in people. These dif-
ferences seem to be related to both genetic and environmental in-
fluences. Especially interesting were the depictions of nonin-
vasive methods allowing epidemiologists to characterize a given
individual's ability to metabolize certain groups ofchemicals. An
example ofthis was the method related by M. A. Butler (National
Center for Toxicologic Research), which requires humans to
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drink coffee and then have their urine analyzed for the manner
in which they metabolize caffeine. This has been found to be
associated with their levels of cytochrome P-450 IA2, which
demethylates caffeine at the 3-position to 1,7-dimethylxanthine.
By determining the ratio of this 1,7-metabolite to others in the
urine, it is possible to assess an individual's P-450 IA2 activity
level. This is important because this P450 enzyme catalyzes the
first step of arylamine activation to metabolites that are car-
cinogenic in the bladder. Studies in Italian and Chinese popula-
tions have shown a bimodal distribution of activity with < 30%
of the populations having high P-450 IA2 activity. Studies are
underway to determine if workers who developed bladder cancer
from exposure to arylamines are rapid caffeine metabolizers with
high P-450 1A2 activity.
F. P. Guengerich (Vanderbilt University) recounted how more
than 20 cDNA sequences were known for human cytochrome
P-450s, but three seem to predominate in their importance in the
activation ofprocarcinogens. These were P-450 IA2, discussed
above, which is also called P-450PA and activates phenacetin,
arylamines, and food pyrolysis products; P-450 IIIA4, also
called P-45ONF, which metabolizes nifedipine, aflatoxins,
polycyclic dihydrodiols, and 6-aminochrysene; and P-450 IIE1,
also called P-450j, which metabolizes ethanol, benzene,
alkylnitrosamines, and chlorinated hydrocarbons. These P-450s
are inducible (e.g., IA2 by cigarette smoke, PAHs etc., and II1A4
by barbiturates). Noninvasive markers of activity are available
for IA2 (caffeine) and IIIA4 (nifedipine), and Guengerich's
group is actively working on a marker for IIEL.
About 40% of the human population lack the i class of
glutathione transferases through gene deletion. Previous studies
have shown a correlation between lack ofglutathione transferase
it and lung cancer risk. J. Wiencke (University ofCalifornia, San
Francisco) discussed how his group demonstrated that lympho-
cytes of persons lacking A transferase are much more suscepti-
ble to genetic damage from epoxides. He indicated, therefore,
that lack ofu transferase may be an important susceptibility factor
for genetic damage from environmental carcinogens.
Differences in the ability ofhumans to metabolize chemicals
via acetylation are well known. W. Weber (University of
Michigan) reported how there has recently been much progress
in understanding the differences within the human population of
the enzymes involved in these particular metabolic processes.
There is promise that we will soon be able to use several nonin-
vasive techniques to characterize the differences in human
populations and their ability to metabolize chemicals.
Biomarkers of Health Effects
Other Than Cancer
The fifth session opened with D. Katz (University ofCalifor-
nia, Davis), summarizing how computer-assisted sperm analysis
can be used to assess male reproductive capability. Using this
technique, his laboratory demonstrated that perchloroethylene
exposure can cause subtle changes in sperm motility, which may
lead to reduced fertility. Another researcher from the University
of California, Davis, B. Lasley, is developing biomarkers of
female reproductive capability based on nonradiometric assays
for urinary metabolites ofpituitary, ovarian, and placental hor-
mones. Such assays could provide a rapid means ofdetecting ear-
ly pregnancy loss and ovarian function in women exposed to toxic
hazards. Much work needs to be done, however, to determine the
endocrine profiles of reproductive abnormalities in normal
women with these methods before the methods can be effectively
used in epidemiological studies.
The need for additional, practical biomarkers to screen for
birth defects was discussed by M. Khoury (Centers for Disease
Control). Cytogenetic characterization of markers such as
trisomy ofchromosome 21 in Downs syndrome should become
much easier with the application of chromosome-specific
fluorescent hybridization probes. The application of molecular
technologies such as the polymerase chain reaction should also
make detection and characterization simpler because only a few
cells are needed. In a series of population-based neurotox-
icological studies, L. Costa (University ofWashington) related
how human lymphocytes express many of the neurochemical
receptors found on nerve cells. This is an important research
advance and presents a myriad of opportunities, empowering
human lymphocytes' use as accessible surrogates for dopamine
and other neurochemical receptors on nerve cells. Analysis of
receptor levels/occupancy on lymphocytes may therefore provide
peripheral markers of neurotoxic effects.
It was reported by C. Snyder (New York University) how dif-
ferent immune function assays can be used as indicators of
chemically induced immune system damage. He also discussed
some of their associated pitfalls. A. Brody (National Institute of
Environmental Health Sciences) portrayed recent progress
toward developing biomarkers ofpulmonary injury, especially
markers of exposure to particulate matter. The best marker of
exposure to particles is the detection ofthe inhaled material at the
sites where the earliest inflammatory lesions and subsequent
disease develop. In animal studies it has been possible to deter-
mine the amount ofparticulates that deposit on the bifurcations
of alveolar ducts. Whether such markers could be useful for
human studies is difficult to predict. By using autoradiography
it is also possible to measure cell proliferation in the lung and to
predict which cell populations are the first to respond to par-
ticulates and noxious agents. For further information on
biomarkers of pulmonary toxicity, readers are referred to the
National Research Council monograph (1).
Liver damage and subsequent cell proliferation could be
measured by release of certain liver-specific growth factors in-
to the bloodstream. G. Michaelopoulos (Duke University
Medical Center) delineated how, for example, hepatopoietin A
is a 100,000 molecular weight liver cell mitogen and growth fac-
tor that is released into the blood during regenerative cell growth
after liver damage. An ELISA assay has been developed to
measure this factor in blood, which may be a highly sensitive
biomarker of subtle damage and hepatic cell proliferation.
Use of Biomarkers in Epidemiology
Studies
The final session ofthe conference concentrated on the current
use ofbiomarkers in epidemiological studies. Case histories of
the use of biomarkers such as protein adducts, DNA adducts,
sister chromatid exchange (SCE), and micronuclei were re-
counted. S. Tannenbaum (Massachusetts Institute of Tech-
nology) began the session by characterizing the use of
hemoglobin adducts to assess exposure to arylamines such as
4-aminobiphenyl (ABP). Working together with epidemiologists
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from the National Cancer Institute and the University ofTurin,
Italy, his group has shown that ABP adduct levels are higher in
smokers ofblack tobacco (as opposed to blonde tobacco), which
is associated with a higher risk ofbladder cancer. Moreover, in
all groups, including nonsmokers, they found about a 50%
higher adduct level in persons of the slow acetylator phenotype.
The adduct level was therefore affected by the type of tobacco
smoked and the individual's acetylator phenotype. F. Perera
(Columbia University) presented a series of large ongoing
epidemiological studies, the objective of which is to correlate
various biomarkers of exposure, effect, and susceptibility in
humans exposed to styrene, aminobiphenyl, ethylene oxide, and
polycyclic aromatic hydrocarbons. Similarly, J. Yager (Electrical
Power Research Institute) reported on a study performed on
styrene-exposed workers in Washington State. Extensive
industrial hygiene measurements ofworker dosimetry were per-
formed on this population so that correlations could be made
between worker exposure and various biomarkers. The
biomarkers studied included DNA adducts, hemoglobin adducts,
and SCE and micronuclei formation in peripheral lymphocytes.
Only SCE induction data were fully analyzed at the time of the
meeting, and Yager delineated statistical approaches to determin-
ing the relative contributions of styrene exposure, cigarette
smoking, age, and other factors. An approximate 10% chem-
ically related increase in SCE levels can be measured by this
approach with statistical significance in 20-40 individuals.
Round-Table Discussion 2
In the final 2 hr of the conference, a second round-table discus-
sion was held. A group of eight epidemiologists and a group of
laboratory scientists were assembled. Both groups were asked
to respond to two questions: How can current biomarkers be used
most effectively? What new types of biomarkers need to be
developed?
M. Schenker (University of California, Davis) started the dis-
cussion by emphasizing the need for biomnarkers of exposure
because of the importance of ascertaining exposures in
epidemiological studies. L. Fine (National Institute ofOccupa-
tional Safety and Health) followed with comments about how
biomarkers ofexposure could be used in intervention studies to
test the effectiveness of particular control strategies. He then
raised an ethical concern regarding the misuse ofbiomarkers of
susceptibility, cautioning that these biomarkers could potentially
and incorrectly serve as a screening mechanism to exclude
groups of workers from the workplace. Fine concluded his
remarks by pointing out that many occupational and environmen-
tal studies are now evaluating nonclassical exposures, such as
those from electrical fields, and that biomarkers need to be
developed that can evaluate these kinds of exposures.
C. Shy (University ofNorth Carolina, Chapel Hill) focused the
discussion on ways of evaluating the effectiveness of using
biomarkers in field investigations. The feasibility ofbiomarkers
as an epidemiological tool could only be determined, for exam-
ple, when the following information is known: what types of
samples need to be collected; how much of the samples can be
stored; and how long the samples can be stored. Shy raised ques-
tions about study and research design that he felt would also have
to be clarified, including determination ofthe size ofthe sample
required in order to have sufficient power, whether serial sam-
pling would be necessary, the associated costs ofcarrying out the
studies, and the level of expertise required both in the field and
in the laboratory. Finally, Shy emphasized the need to correlate
biomarkers with the standard techniques currently used to
evaluate exposures and the need for "gold standards" to assess
their validity.
The importance of correlating the presence or level of a par-
ticular biomarker with a clinical outcome was highlighted by H.
Checkoway (University ofWashington). Through such correla-
tion, the significance ofdetecting a change in a biomarker could
be ascertained. His remarks were followed by J. Andrews (Agen-
cy for Toxic Substances and Disease Registry), who counseled
investigators to use biomarkers in field studies so that the validity,
sensitivity, and usefulness ofthe studies could be determined. A.
Caporaso (National Cancer Institute) concurred that the use of
biomarkers as measures ofexposure, dose, or susceptibility must
be validated in epidemiological studies and urged epidemi-
ologists to work closely with laboratory scientists.
Addressing the use ofa biomarker as a tool in epidemiological
investigations, A. Wilcox (National Institute of Environmental
Health Sciences) pointed out that epidemiologists need simple,
well-characterized, repeatable standard assays that can be ap-
plied in studies ofhundreds or thousands ofpeople. Underscor-
ing those remarks, S. Swan (California Department of Health
Services) then drew the audience's attention to the potential pro-
blem of sample and selection bias that would arise if specially
self-selected groups within the population were more likely to
participate in studies where samples of urine or semen, for
example, were collected on a regular basis. She also suggested
conducting paired studies to compare the more traditional
epidemiological measures with biomarkers currently being
developed.
Perera concluded the discussion among the first group of
scientists by suggesting that the most effective use ofbiomarkers
would be to incorporate them in a series or battery of tests to be
performed in a population-based study, and including both
specific and generic types of markers. She also commented on
the utility ofcomparing biomarkers in human and animal studies
and how such correlative studies would provide opportunities to
more fully validate promising biomarkers.
The second group of scientists assembled with Smith leading
the discussion. He pointed out the importance ofbiomarkers of
effect because of the latency period often involved with cancer
and other forms of disease. He also raised the prospect of
technology transfer oftechniques currently being developed and
suggested that the techniques could be transferred to large
government or contract laboratories that could perform analyses
on large numbers of samples. This would help bridge the gap be-
tween development laboratories and field epidemiologists. Final-
ly, Smith brought up the ethical dilemma that will face scientists
when studies are conducted involving individuals living near
Superfund sites. What do the investigators tell the public? How
do scientists disseminate information about the significance of
the presence ofbiomarkers and how they correlate to risk ofdis-
ease? How are the uncertainties about risk estimates explained?
W. Suk (National Institute ofEnvironmental Health Sciences)
framed his comments within the context ofthe goals ofthe Super-
fund Basic Research Program. He stressed the importance ofthe
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need for epidemiologists and molecular biologists to work
together in the development and validation of advanced tech-
niques for the detection, assessment, and evaluation ofthe effects
on human health ofhazardous substances, especially at low levels
of exposure. Furthermore, he explained that new and cogent
methods to assess the risks to human health presented by hazard-
ous substances need to be effectively dealt with ifone is to take
basic research and implement it practically and productively in
the field. Suk then elaborated on Smith's comments about tech-
nology transfer and added that he viewed epidemiologists as
instrumental in carrying out this transfer as biomarkers are
moved from the laboratories to the field.
Emphasizing the necessity of developing predictive bio-
markers and urging that the scientific community not settle for
poorly characterized markers, C. Harris (National Cancer In-
stitute) pointed out that such research efforts will require a large
expenditure of funds. He called for continued investigation in-
to molecular mechanisms in developing biomarkers of effect for
cancer. It is his opinion that investigators should focus future ef-
forts on tumor-suppressor genes, not activated oncogenes, and
concentrate on developing technologies for markers ofeffect in
this area. He was confident that these tools would be forthcom-
ing but that they would involve sophisticated techniques and
would be expensive. Harris ended with remarks about our grow-
ing understanding of genetic predisposition as a factor affecting
an individual's risk of disease and reiterated earlier comments
about the ethical issues that are raised surrounding potential
worker discrimination issues.
The need to incorporate relevant biomarkers into monitoring
and animal studies and to have these studies examine different end
points todetermine ifthebiomarkers arepredictive inthese mod-
els was the focus ofYager's comments. She also raised the ques-
tion ofhow to determine when an assay is robustenough (i.e., pre-
dictable enough, sensitive enough, specific enough) to be used.
Finally, she underscored the need to identify the sources ofbiolog-
ical variability in the development and application ofbiomarkers.
The final remarks from the group came from Wogan, who re-
emphasized comments made earlier about the practicability and
accessibility of the sample material. He added that application
of biomarkers to broad segments of the population would be
limited unless techniques developed in the laboratories could be
translated into field procedures applied to readily accessible
bodily fluids. Wogan then provided the group with a historical
perspective by pointing out that the development of science has
been driven in the past by the emergence ofnew and important
technologies and that he foresaw an exciting period of cancer
research ahead. Furthermore, as technologies acquired
usefulness, the associated costs would decline and he was hopeful
that the new biomarker technologies currently being developed
could be made cost effective.
Summary
The principal conclusions and opportunities that can be drawn
from this conference are as follows. The meeting demonstrated
the large communication gap that still exists between most
epidemiologists and laboratory scientists. This problem could be
overcome if epidemiologists worked closely with laboratory
scientists at the outset ofany project so that a better understand-
ing could be built between them. Epidemiologists need simple,
well-characterized, reproducible assays that can be applied to
hundreds or thousands ofpeople. Most laboratory scientists have
little interest in running large numbers ofassays, but wish to con-
tinually refine their methods so that they stay on the "cutting
edge" ofbasic research. This problem could be overcome if the
new laboratory technology could be transferred to contract
laboratories or small companies. Problems of technology
transfer therefore need to be addressed. Current and new
biomarkers need to be better validated in the field and by study-
ing animal models. More information on the background expres-
sion ofbiomarkers in the general population is needed (i.e. what
is the normal range?). Ethical issues, such as the possibility that
biomarkers of susceptibility could be used to exclude people
from the workplace, need to be addressed.
Appendix
Application of Molecular Biomarkers in
Epidemiology: Program
Welcome and NIEHS view
D. Rall, NIEHS
Introduction to Meeting
M. Smith, University of California, Berkeley
Epidemiological criteria for the perfect biomarker
R. Neutra, NIEHS
IARC view of biomarkers
R. Montesano,
Session I
Overview, biomarkers of genetic damage
M. Smith, University of California, Berkely
Mutational spectra at hprt and other loci
W. Tilly, Massachusetts Institute ofTechnology
hprt Mutations in T-lymphocytes
R. Albertini, University of Vermont
Glycophorin A assay
W. Bigbee, Lawrence Livermore National Laboratory
Micronuclei formation in human blood cells
J. McGregor, SRI International
Relationships between various markers ofdamage in blood cells
G. Lucier, NIEHS
Biomarkers of promotion
B. Weinstein, Columbia University
Session 11
Overview, immunological approaches to assessing exposure
B. Hammock, University of California, Davis
Monoclonal antibodies to blood protein adducts
R. Haas, California Department of Health Services
PAH esters in human hemoglobin
P. Skipper, Massachusetts Institute of Technology
Cysteinyl adducts in blood proteins
S. Rappaport, University of North Carolina, Chapel Hill
DNA-protein crosslinks as biomarkers of exposure
M. Costa, New York University
DNA adducts as biomarkers
K. Hemminki, University of Helsinki
Urinary metabolites
A. Buckpitt, University of California, Davis
Session III
Relationships between DNA adducts, cell proliferation, and carcinogenesis
J. Swenberg, University of North Carolina, Chapel Hill
Correlations ofhemoglobin adducts, DNA adducts, and urinary metabolites
R. Henderson, Lovelace Inhalation Toxicology Research Institute
Correlations between DNA modifications, oncogene activation, and
hepatocarcinogenesis
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Session IV
G. Wogan, Massachusetts Institute ofTechnology
Phenotypic differences in cytochrome P-450
F. P. Guengerich, Vanderbilt University
Arylamine carcinogenesis and caffeine 3-demethylation as a biomarker
in humans
M. A. Butler, National Center for Toxicological Research
Human glutathione transferase it deficiency
J. Wiencke, University of California, San Francisco
Acetyltransferase polymorphism
W. Weber, University of Michigan
Session V
Assessment of male reproductive capability
D. Katz, University of California, Davis
Assessment of female reproductive capability
B. Lasley, University of California, Davis
Biomarkers of birth defects
M. Khoury, Centers for Disease Control
Peripheral markers of neurotoxicity
L. Costa, University of Washington
Immune function assays as indicators of toxicant exposure
C. Snyder, New York University
Biomarkers of lung injury
A. Brody, National Institute of Environmental Health Sciences
Biomarkers of liver injury
G. Michalopoulos, Duke University Medical Center
Session VI
Arylamines
S. Tannenbaum, Massachusetts Institute of Technology
Polycyclic aromatic hydrocarbons and other carcinogens
F.Perera, Columbia University
Styrene
J. Yager, Electrical Power Research Institute
Peripheral markers of styrene toxicity
H. Checkoway, University ofWashington
Aflatoxin
J. Groopman, Johns Hopkins University
Inherited predisposition and molecular dosimetry in cancer risk
C. Harris, National Cancer Institute
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